# Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

> **NCT02404935** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 139 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** FOLFIRI and cetuximab

## Key facts

- **NCT ID:** NCT02404935
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-22
- **Primary completion:** 2020-11-01
- **Final completion:** 2021-10-25
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02404935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02404935, "Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02404935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*